Company news

Apellis Pharmaceuticals, Inc. news in 2026

Apellis Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

July 9, 2026

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

March 30, 2026

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

March 1, 2026

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

February 24, 2026

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

February 22, 2026

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

February 18, 2026

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

February 10, 2026

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026